TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 40
1.4 LIMITATIONS 42
1.5 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 CURRENCY AND PRICING 47
2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.7 MULTIVARIATE MODELLING 52
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 52
2.9 DBMR MARKET POSITION GRID 53
2.10 VENDOR SHARE ANALYSIS 55
2.11 MARKET END USER COVERAGE GRID 56
2.12 SECONDARY SOURCES 57
2.13 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHTS 62
4.1 PORTERS FIVE FORCES 64
4.2 PESTEL ANALYSIS 65
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 66
4.3.1 CEPHEID 66
4.3.2 THERMO FISHER SCIENTIFIC INC. 67
4.3.3 HOLOGIC, INC. 68
4.3.4 BD 69
4.3.5 F. HOFFMANN-LA ROCHE LTD 70
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 71
4.5 DISTRIBUTORS 72
4.5.1 NORTH AMERICA 72
4.5.2 EUROPE 73
4.5.3 SOUTH ASIA 75
4.5.4 SOUTH EAST ASIA 76
4.5.5 MIDDLE EAST 78
4.5.6 AFRICA 79
5 REGULATORY FRAMEWORK 80
6 MARKET OVERVIEW 83
6.1 DRIVERS 85
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 85
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 85
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 86
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 86
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 87
6.2 RESTRAINTS 88
6.2.1 PRODUCT RECALLS 88
6.2.2 HIGH COSTS OF PRODUCTS 88
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 89
6.3 OPPORTUNITIES 89
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 89
6.3.2 RISING HEALTHCARE EXPENDITURE 90
6.3.3 PANDEMIC OUTBREAK OF COVID-19 91
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 91
6.4 CHALLENGES 92
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 92
6.4.2 LACK OF ACCESSIBILITY 92
7 IMPACT OF COVID-19 ON THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 94
7.1 IMPACT ON PRICE 94
7.2 IMPACT ON DEMAND 94
7.3 IMPACT ON SUPPLY CHAIN 95
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 95
7.5 CONCLUSION: 96
8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 97
8.1 OVERVIEW 98
8.2 CONSUMABLES & REAGENTS 101
8.3 INSTRUMENTS 101
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 102
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 102
9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 103
9.1 OVERVIEW 104
9.2 RESPIRATORY INFECTIONS TESTING 107
9.2.1 COVID-19 108
9.2.2 FLU B 108
9.2.3 FLU A 108
9.2.4 RSV 108
9.2.5 TUBERCULOSIS 108
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 108
9.2.7 OTHERS 109
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 109
9.3.1 TV 110
9.3.2 CT 110
9.3.3 NG 110
9.3.4 HPV 110
9.3.5 HSV 110
9.3.6 MG 110
9.3.7 UU 111
9.3.8 MH 111
9.3.9 OTHERS 111
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 111
9.4.1 GROUP B STREPTOCOCCUS 112
9.4.2 SHIGA TOXIN 112
9.4.3 H. PYLORI 112
9.5 OTHERS 113
10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 114
10.1 OVERVIEW 115
10.2 LABORATORIES 118
10.2.1 POLYMERASE CHAIN REACTION 119
10.2.2 ISOTHERMAL AMPLIFICATION 119
10.3 HOSPITAL 119
10.3.1 POLYMERASE CHAIN REACTION 120
10.3.2 ISOTHERMAL AMPLIFICATION 120
10.4 CLINICS 120
10.4.1 POLYMERASE CHAIN REACTION 121
10.4.2 ISOTHERMAL AMPLIFICATION 121
10.5 AMBULATORY CENTER 121
10.5.1 POLYMERASE CHAIN REACTION 122
10.5.2 ISOTHERMAL AMPLIFICATION 122
10.6 HOMECARE 122
10.6.1 POLYMERASE CHAIN REACTION 123
10.6.2 ISOTHERMAL AMPLIFICATION 123
10.7 ASSISTED LIVING FACILITIES 124
10.7.1 POLYMERASE CHAIN REACTION 124
10.7.2 ISOTHERMAL AMPLIFICATION 124
10.8 OTHERS 125
11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 126
11.1 OVERVIEW 127
11.2 PRESCRIPTION-BASED TESTING 130
11.3 OTC TESTING 131
12 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 132
12.1 OVERVIEW 133
12.2 HOSPITAL PHARMACY 136
12.3 RETAIL PHARMACY 137
12.4 ONLINE PHARMACY 138
13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 139
13.1 OVERVIEW 140
13.2 NORTH AMERICA 145
13.2.1 U.S. 154
13.2.2 CANADA 159
13.3 EUROPE 164
13.3.1 U.K. 174
13.3.2 GERMANY 179
13.3.3 ITALY 184
13.3.4 FRANCE 189
13.3.5 SPAIN 194
13.3.6 REST OF EUROPE 199
13.4 SOUTH ASIA 200
13.4.1 INDIA 209
13.4.2 PAKISTAN 214
13.4.3 BANGLADESH 219
13.4.4 REST OF SOUTH ASIA 224
13.5 SOUTH EAST ASIA 225
13.5.1 SINGAPORE 234
13.5.2 VIETNAM 239
13.5.3 THAILAND 244
13.5.4 MALAYSIA 249
13.5.5 INDONESIA 254
13.5.6 PHILIPPINES 259
13.5.7 REST OF SOUTH EAST ASIA 264
13.6 MIDDLE EAST 265
13.6.1 SAUDI ARABIA 274
13.6.2 U.A.E 279
13.6.3 ISRAEL 284
13.6.4 EGYPT 289
13.6.5 REST OF MIDDLE EAST 294
13.7 AFRICA 295
13.7.1 SOUTH AFRICA 304
13.7.2 KENYA 309
13.7.3 NIGERIA 314
13.7.4 REST OF AFRICA 319
14 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 320
14.1 COMPANY SHARE ANALYSIS: GLOBAL 320
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 321
14.3 COMPANY SHARE ANALYSIS: EUROPE 322
14.4 COMPANY SHARE ANALYSIS: SOUTH ASIA 323
15 SWOT ANALYSIS 324
16 COMPANY PROFILE 325
16.1 DANAHER 325
16.1.1 COMPANY SNAPSHOT 325
16.1.2 REVENUE ANALYSIS 325
16.1.3 COMPANY SHARE ANALYSIS 326
16.1.4 PRODUCT PORTFOLIO 326
16.1.5 RECENT DEVELOPMENTS 327
16.2 THERMO FISHER SCIENTIFIC INC. 328
16.2.1 COMPANY SNAPSHOT 328
16.2.2 REVENUE ANALYSIS 328
16.2.3 COMPANY SHARE ANALYSIS 329
16.2.4 PRODUCT PORTFOLIO 329
16.2.5 RECENT DEVELOPMENTS 329
16.3 BD 330
16.3.1 COMPANY SNAPSHOT 330
16.3.2 REVENUE ANALYSIS 330
16.3.3 COMPANY SHARE ANALYSIS 331
16.3.4 PRODUCT PORTFOLIO 331
16.3.5 RECENT DEVELOPMENTS 331
16.4 F.HOFFMANN-LA-ROCHE LTD. 332
16.4.1 COMPANY SNAPSHOT 332
16.4.2 REVENUE ANALYSIS 332
16.4.3 COMPANY SHARE ANALYSIS 333
16.4.4 PRODUCT PORTFOLIO 333
16.4.5 RECENT DEVELOPMENTS 334
16.5 ABBOTT 335
16.5.1 COMPANY SNAPSHOT 335
16.5.2 REVENUE ANALYSIS 335
16.5.3 PRODUCT PORTFOLIO 336
16.5.4 RECENT DEVELOPMENTS 336
16.6 BINX HEALTH, INC. 337
16.6.1 COMPANY SNAPSHOT 337
16.6.2 PRODUCT PORTFOLIO 337
16.6.3 RECENT DEVELOPMENT 337
16.7 BIOMERIEUX SA 338
16.7.1 COMPANY SNAPSHOT 338
16.7.2 REVENUE ANALYSIS 338
16.7.3 PRODUCT PORTFOLIO 339
16.7.4 RECENT DEVELOPMENT 339
16.8 CO-DIAGNOSTICS, INC. 340
16.8.1 COMPANY SNAPSHOT 340
16.8.2 REVENUE ANALYSIS 340
16.8.3 PRODUCT PORTFOLIO 341
16.8.4 RECENT DEVELOPMENTS 341
16.9 GENMARK DIAGNOSTICS, INC 342
16.9.1 COMPANY SNAPSHOT 342
16.9.2 REVENUE ANALYSIS 342
16.9.3 PRODUCT PORTFOLIO 343
16.9.4 RECENT DEVELOPMENT 343
16.10 GRIFOLS, S.A. 344
16.10.1 COMPANY SNAPSHOT 344
16.10.2 REVENUE ANALYSIS 344
16.10.3 PRODUCT PORTFOLIO 345
16.10.4 RECENT DEVELOPMENT 345
16.11 LUCIRA HEALTH INC. 346
16.11.1 COMPANY SNAPSHOT 346
16.11.2 PRODUCT PORTFOLIO 346
16.11.3 RECENT DEVELOPMENTS 346
16.12 MERIDIAN BIOSCIENCE 347
16.12.1 COMPANY SNAPSHOT 347
16.12.2 REVENUE ANALYSIS 347
16.12.3 PRODUCT PORTFOLIO 348
16.12.4 RECENT DEVELOPMENTS 348
16.13 QUANTUMDX GROUP LTD. 349
16.13.1 COMPANY SNAPSHOT 349
16.13.2 PRODUCT PORTFOLIO 349
16.13.3 RECENT DEVELOPMENTS 349
16.14 QUIDEL CORPORATION 351
16.14.1 COMPANY SNAPSHOT 351
16.14.2 REVENUE ANALYSIS 351
16.14.3 PRODUCT PORTFOLIO 352
16.14.4 RECENT DEVELOPMENT 352
16.15 SD BIOSENSOR, INC. 353
16.15.1 COMPANY SNAPSHOT 353
16.15.2 PRODUCT PORTFOLIO 353
16.15.3 RECENT DEVELOPMENT 353
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 354
16.16.1 COMPANY SNAPSHOT 354
16.16.2 PRODUCT PORTFOLIO 354
16.16.3 RECENT DEVELOPMENT 354
16. SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 356
16.17.1 COMPANY SNAPSHOT 356
16.17.2 REVENUE ANALYSIS 356
16.17.3 PRODUCT PORTFOLIO 357
16.17.4 RECENT DEVELOPMENT 357

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.